SCHEMBL5732740

SCHEMBL5732740

Cc1cc(Cl)ccc1-c1cccc(C(O)CCC2CCC(=O)N2CCCCCCC(=O)O)c1

nearest known ligand 0.84

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 12/20 0.84
PTGER2 P43116 6/20 0.84
PTGER3 P43115 3/20 0.73
PTGER1 P34995 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5732737 1.00 PTGER4 (0.84) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5732735 1.00 PTGER4 (0.84) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5732901 0.91 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5732904 0.91 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5215300 0.91 PTGER4 (0.93) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5215619 0.91 PTGER4 (0.93) PTGER4PTGER2PTGER3PTGER1
SCHEMBL4933370 0.87 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1
SCHEMBL4940941 0.87 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1
SCHEMBL4940936 0.87 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1
SCHEMBL5733077 0.84 PTGER4 (1.00) PTGER4PTGER2PTGER3PTGER1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP claimed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US claimed
EP-1409455-A1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2004-04-21 EP claimed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US claimed
WO-2003008377-A1 PROSTAGLANDIN ANALOGUES_AS EP4 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2003-01-30 WO claimed
EP-1409455-B1 PROSTAGLANDIN ANALOGUES-AS EP4 RECEPTOR AGONISTS HOFFMANN LA ROCHE (CH) 2006-01-04 EP disclosed
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 PTGER4 1/4885PTGER2 15/4885PTGER3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.